一个纳米粒子平台,用于结合粘膜治疗和免疫调节,用于治疗炎症性肠病
Valentina Marotti1, Yining Xu1, Cécilia Bohns Michalowski1
1UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium.
Bioactive materials
|October 20, 2023
概括
研究人员开发了新的纳米粒子,以促进肠道愈合和减少炎症,用于炎症性肠病 (IBD) 治疗. 这种双重作用的方法将生长因子与向免疫调节结合起来,提供了一个有前途的新疗法策略.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 胃肠病学 胃肠病学
背景情况:
- 目前的炎症性肠病 (IBD) 治疗主要依赖于抗炎药物.
- 需要治疗方法,促进肠道愈合,同时管理IBD的炎症.
研究的目的:
- 开发一种基于纳米粒子的系统,用于诱导类似葡萄糖2 (GLP-2) 的分泌,以促进肠道生长.
- 通过功能化纳米粒子表面来实现同时免疫调节.
- 创建IBD的组合疗法使用纳米颗粒装载着teduglutide和表面结合.
主要方法:
- 开发混合脂质纳米颗粒与氨酸-KPV结合.
- 装载纳米颗粒与teduglutide,一个GLP-2模拟.
- 评估基于氨酸-KPV表面功能化的免疫调节效应.
主要成果:
- 开发的纳米载体表现出可调节的免疫抑制,基于氨酸-KPV功能化的存在或不存在.
- 该策略成功地将粘膜愈合促进 (通过泰杜格卢) 与免疫调节相结合.
结论:
- 新型纳米粒子平台为IBD的联合治疗提供了一个有前途的方法.
- 这一策略能够同时进行粘膜愈合和免疫调节,解决IBD病理学的关键方面.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
461
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
461
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
517
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
517
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338


